Loading...
Market
Asciminib (Scemblix) major molecular response rate by end of 2025?
3
Resolution / Starting Odds
Less than 25% • 25%
25% to 30% • 25%
30% to 35% • 25%
More than 35% • 25%
Publication of clinical trial results in medical journals or announcements by Novartis
Story
FDA Grants Accelerated Approval for Novartis's Asciminib (Scemblix) for CML, 25% Major Molecular Response Rate
Oct 29, 2024, 05:35 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novartis's asciminib (brand name Scemblix) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Clinical trials demonstrated a 25% major molecular response rate at 24 weeks for asciminib, compared to 13% for the previous standard treatment, bosutinib. This approval positions asciminib as a promising option for frontline therapy in this patient population. Further application reviews are ongoing with other regulatory agencies, including Health Canada.
View original story
Similar markets
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 50% • 25%
50-60% • 25%
60-70% • 25%
More than 70% • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Less than 40% • 25%
40% to 49% • 25%
50% to 59% • 25%
60% or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%